IL‐1β has been identified as a main inflammatory mediator of eliciting islet β‐cell injury in diabetes,4 and animal studies and clinical trials blocking IL‐1β signalling pathway have proved to ameliorate β‐cell function and improve glucose homeostasis in DM,5, 6 yet the mechanism by which IL‐1β impairs islet β‐cell biology is not completely understood. Here, IL1B is linked to diabetes mellitus.